DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 
Phase 2 trial tested olaparib 300mg BID in 31 patients with advanced biliary tract cancer and HRR mutations. Most had intrahepatic disease and prior systemic therapy.
⚕️ Key Clinical Considerations ⚕️
- Limited Response Rate: Only 6.5% objective response rate with 1 complete and 1 partial response.
- Disease Stabilization: 74% disease control rate suggests olaparib may slow progression in select patients.
- Mutation-Specific Activity: Complete response in ATM mutation, partial response in germline BRCA1 mutation.
- Manageable Toxicity: 25% grade 3-4 treatment-related AEs, primarily hematologic (anemia most common).
- Modest Survival Benefit: 16.7 weeks median PFS and 11.2 months overall survival in heavily pretreated population.
🎯 Clinical Practice Impact 🎯
- Results support genetic testing for HRR mutations in advanced biliary tract cancer patients.
- Olaparib offers a treatment option for the subset with these mutations, particularly after chemotherapy failure.
- The low response rate suggests need for better biomarker selection and combination strategies.
More in Hepatology
